{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:22:10Z","timestamp":1787019730211,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We have previously reported that expression of the RNA- and DNA-binding protein RBM3 is associated with a good prognosis in breast cancer and ovarian cancer. In this study, the prognostic value of immunohistochemical RBM3 expression was assessed in incident cases of malignant melanoma from a prospective population-based cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Until Dec 31\n                      <jats:sup>st<\/jats:sup>\n                      2008, 264 incident cases of primary invasive melanoma had been registered in the Malm\u00f6 Diet and Cancer Study. Histopathological and clinical information was obtained for available cases and tissue microarrays (TMAs) constructed from 226 (85.6%) suitable paraffin-embedded tumours and 31 metastases. RBM3 expression was analysed by immunohistochemistry on the TMAs and a subset of full-face sections. Chi-square and Mann-Whitney U tests were used for comparison of RBM3 expression and relevant clinicopathological characteristics. Kaplan Meier analysis and Cox proportional hazards modelling were used to assess the relationship between RBM3 and recurrence free survival (RFS) and overall survival (OS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RBM3 could be assessed in 215\/226 (95.1%) of primary tumours and all metastases. Longitudinal analysis revealed that 16\/31 (51.6%) of metastases lacked RBM3 expression, in contrast to the primary tumours in which RBM3 was absent in 3\/215 (1.4%) cases and strongly expressed in 120\/215 (55.8%) cases. Strong nuclear RBM3 expression in the primary tumour was significantly associated with favourable clinicopathological parameters; i.e. non-ulcerated tumours, lower depth of invasion, lower Clark level, less advanced clinical stage, low mitotic activity and non-nodular histological type, and a prolonged RFS (RR = 0.50; 95% CI = 0.27-0.91) and OS (RR = 0.36, 95%CI = 0.20-0.64). Multivariate analysis demonstrated that the beneficial prognostic value of RBM3 remained significant for OS (RR = 0.33; 95%CI = 0.18-0.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In line with previous in vitro data, we here show that RBM3 is down-regulated in metastatic melanoma and high nuclear RBM3 expression in the primary tumour is an independent marker of a prolonged OS. The potential utility of RBM3 in treatment stratification of patients with melanoma should be pursued in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1479-5876-9-114","type":"journal-article","created":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T14:21:55Z","timestamp":1311258115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the Malm\u00f6 Diet and Cancer Study"],"prefix":"10.1186","volume":"9","author":[{"given":"Liv","family":"Jonsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Nodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Manjer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Pont\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Uhl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,21]]},"reference":[{"key":"782_CR1","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1200\/JCO.2006.08.1463","volume":"25","author":"PA Gimotty","year":"2007","unstructured":"Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D: Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007, 25: 1129-1134. 10.1200\/JCO.2006.08.1463.","journal-title":"J Clin Oncol"},{"key":"782_CR2","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/cncr.20602","volume":"101","author":"C Lindholm","year":"2004","unstructured":"Lindholm C, Andersson R, Dufmats M, Hansson J, Ingvar C, Moller T, Sjodin H, Stierner U, Wagenius G: Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer. 2004, 101: 2067-2078. 10.1002\/cncr.20602.","journal-title":"Cancer"},{"key":"782_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cncr.11624","volume":"98","author":"JG McKinnon","year":"2003","unstructured":"McKinnon JG, Yu XQ, McCarthy WH, Thompson JF: Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003, 98: 1223-1231. 10.1002\/cncr.11624.","journal-title":"Cancer"},{"key":"782_CR4","first-page":"627","volume":"9","author":"VK Sondak","year":"2006","unstructured":"Sondak VK, Messina JL: Current status of biomarkers for melanoma metastasis. IDrugs. 2006, 9: 627-631.","journal-title":"IDrugs"},{"key":"782_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/35020115","volume":"406","author":"M Bittner","year":"2000","unstructured":"Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V: Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000, 406: 536-540. 10.1038\/35020115.","journal-title":"Nature"},{"key":"782_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/jnci\/djj103","volume":"98","author":"V Winnepenninckx","year":"2006","unstructured":"Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A: Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006, 98: 472-482. 10.1093\/jnci\/djj103.","journal-title":"J Natl Cancer Inst"},{"key":"782_CR7","doi-asserted-by":"crossref","unstructured":"Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, Lillehaug JR, Borg A, Lonning PE: Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res. 16: 3356-3367.","DOI":"10.1158\/1078-0432.CCR-09-2509"},{"key":"782_CR8","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1093\/hmg\/4.12.2307","volume":"4","author":"JM Derry","year":"1995","unstructured":"Derry JM, Kerns JA, Francke U: RBM3, a novel human gene in Xp11.23 with a putative RNA-binding domain. Hum Mol Genet. 1995, 4: 2307-2311. 10.1093\/hmg\/4.12.2307.","journal-title":"Hum Mol Genet"},{"key":"782_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1006\/bbrc.1997.7059","volume":"236","author":"S Danno","year":"1997","unstructured":"Danno S, Nishiyama H, Higashitsuji H, Yokoi H, Xue JH, Itoh K, Matsuda T, Fujita J: Increased transcript level of RBM3, a member of the glycine-rich RNA-binding protein family, in human cells in response to cold stress. Biochem Biophys Res Commun. 1997, 236: 804-807. 10.1006\/bbrc.1997.7059.","journal-title":"Biochem Biophys Res Commun"},{"key":"782_CR10","doi-asserted-by":"crossref","unstructured":"Lleonart ME: A new generation of proto-oncogenes: cold-inducible RNA binding proteins. Biochim Biophys Acta. 1805: 43-52.","DOI":"10.1016\/j.bbcan.2009.11.001"},{"key":"782_CR11","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1074\/mcp.M500279-MCP200","volume":"4","author":"M Uhlen","year":"2005","unstructured":"Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Herkules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Sk\u00f6llermo A, Steen J, Stenvall M, Sterky F, Str\u00f6mberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Wald\u00e9n A, Wan J, Wern\u00e9rus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Pont\u00e9n F: A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005, 4: 1920-1932. 10.1074\/mcp.M500279-MCP200.","journal-title":"Mol Cell Proteomics"},{"key":"782_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1074\/mcp.M700411-MCP200","volume":"7","author":"E Bjorling","year":"2008","unstructured":"Bjorling E, Lindskog C, Oksvold P, Linne J, Kampf C, Hober S, Uhlen M, Ponten F: A web-based tool for in silico biomarker discovery based on tissue-specific protein profiles in normal and cancer tissues. Mol Cell Proteomics. 2008, 7: 825-844. 10.1074\/mcp.M700411-MCP200.","journal-title":"Mol Cell Proteomics"},{"key":"782_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.2440","volume":"216","author":"F Ponten","year":"2008","unstructured":"Ponten F, Jirstrom K, Uhlen M: The Human Protein Atlas--a tool for pathology. J Pathol. 2008, 216: 387-393. 10.1002\/path.2440.","journal-title":"J Pathol"},{"key":"782_CR14","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/modpathol.2009.124","volume":"22","author":"A Jogi","year":"2009","unstructured":"Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S, Uhlen M, Landberg G, Pahlman S, Jirstrom K: Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol. 2009, 22: 1564-1574. 10.1038\/modpathol.2009.124.","journal-title":"Mod Pathol"},{"key":"782_CR15","doi-asserted-by":"crossref","unstructured":"Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, Ponten F, Jirstrom K: Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. 8: 78-","DOI":"10.1186\/1479-5876-8-78"},{"key":"782_CR16","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1038\/onc.2008.97","volume":"27","author":"SM Sureban","year":"2008","unstructured":"Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, Houchen CW, Anant S: Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene. 2008, 27: 4544-4556. 10.1038\/onc.2008.97.","journal-title":"Oncogene"},{"key":"782_CR17","doi-asserted-by":"crossref","unstructured":"Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, Buhrer C: The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res. 67: 35-41.","DOI":"10.1203\/PDR.0b013e3181c13326"},{"key":"782_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/jcb.20725","volume":"97","author":"F Martinez-Arribas","year":"2006","unstructured":"Martinez-Arribas F, Agudo D, Pollan M, Gomez-Esquer F, Diaz-Gil G, Lucas R, Schneider J: Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer. J Cell Biochem. 2006, 97: 1275-1282. 10.1002\/jcb.20725.","journal-title":"J Cell Biochem"},{"key":"782_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/jcb.20204","volume":"94","author":"LC Sutherland","year":"2005","unstructured":"Sutherland LC, Rintala-Maki ND, White RD, Morin CD: RNA binding motif (RBM) proteins: a novel family of apoptosis modulators?. J Cell Biochem. 2005, 94: 5-24. 10.1002\/jcb.20204.","journal-title":"J Cell Biochem"},{"key":"782_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1034\/j.1600-0625.2003.00026.x","volume":"12","author":"A Baldi","year":"2003","unstructured":"Baldi A, Battista T, De Luca A, Santini D, Rossiello L, Baldi F, Natali PG, Lombardi D, Picardo M, Felsani A, Paggi MG: Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol. 2003, 12: 213-218. 10.1034\/j.1600-0625.2003.00026.x.","journal-title":"Exp Dermatol"},{"key":"782_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2796.1993.tb00647.x","volume":"233","author":"G Berglund","year":"1993","unstructured":"Berglund G, Elmstahl S, Janzon L, Larsson SA: The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med. 1993, 233: 45-51. 10.1111\/j.1365-2796.1993.tb00647.x.","journal-title":"J Intern Med"},{"key":"782_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/00008469-200112000-00003","volume":"10","author":"J Manjer","year":"2001","unstructured":"Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G: The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001, 10: 489-499. 10.1097\/00008469-200112000-00003.","journal-title":"Eur J Cancer Prev"},{"key":"782_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/nm0798-844","volume":"4","author":"J Kononen","year":"1998","unstructured":"Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med. 1998, 4: 844-847. 10.1038\/nm0798-844.","journal-title":"Nat Med"},{"key":"782_CR24","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","volume":"23","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumour marker prognostic studies. J Clin Oncol. 2005, 23: 9067-9072. 10.1200\/JCO.2004.01.0454.","journal-title":"J Clin Oncol"},{"key":"782_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322\/caac.20006.","journal-title":"CA Cancer J Clin"},{"key":"782_CR26","doi-asserted-by":"crossref","unstructured":"Gimotty PA, Guerry D: Prognostication in thin cutaneous melanomas. Arch Pathol Lab Med. 134: 1758-1763.","DOI":"10.5858\/2009-0653-RAR.1"},{"key":"782_CR27","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/cncr.22511","volume":"109","author":"KG Lasithiotakis","year":"2007","unstructured":"Lasithiotakis KG, Leiter U, Eigentler T, Breuninger H, Metzler G, Meier F, Garbe C: Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed?. Cancer. 2007, 109: 1174-1182. 10.1002\/cncr.22511.","journal-title":"Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-9-114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:30:15Z","timestamp":1630495815000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-9-114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-9-114","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,21]]},"assertion":[{"value":"31 March 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"114"}}